Invention Grant
- Patent Title: Nucleoside kinase bypass compositions and methods
-
Application No.: US14648726Application Date: 2013-12-02
-
Publication No.: US09624249B2Publication Date: 2017-04-18
- Inventor: Gabor Butora
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Yong Zhao; John C. Todaro
- International Application: PCT/US2013/072540 WO 20131202
- International Announcement: WO2014/088923 WO 20140612
- Main IPC: C07D339/08
- IPC: C07D339/08 ; C07D407/04 ; C07D409/12 ; C07D409/14 ; C07D487/04 ; C07F9/6561 ; C07F9/6553 ; C07F9/6558 ; C07F9/6571 ; C07F9/6574
Abstract:
The present invention relates to disulfide masked prodrug compounds of Formula (I), nucleoside kinase bypass compositions thereof and methods that are amenable to bioactivation by a reducing agent such as glutathione: Such disulfide based compounds, compositions, and methods can be useful, for example, in providing prodrugs for use as therapeutics.
Public/Granted literature
- US20150315221A1 NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS Public/Granted day:2015-11-05
Information query
